• Something wrong with this record ?

In Vivo Performance and Properties of Tamoxifen Metabolites for CreERT2 Control

A. Felker, S. Nieuwenhuize, A. Dolbois, K. Blazkova, C. Hess, LW. Low, S. Burger, N. Samson, TJ. Carney, P. Bartunek, C. Nevado, C. Mosimann,

. 2016 ; 11 (4) : e0152989. [pub] 20160414

Language English Country United States

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc16027545

Mutant Estrogen Receptor (ERT2) ligand-binding domain fusions with Cre recombinase are a key tool for spatio-temporally controlled genetic recombination with the Cre/lox system. CreERT2 is efficiently activated in a concentration-dependent manner by the Tamoxifen metabolite trans-4-OH-Tamoxifen (trans-4-OHT). Reproducible and efficient Cre/lox experimentation is hindered by the gradual loss of CreERT2 induction potency upon prolonged storage of dissolved trans-4-OHT, which potentially results from gradual trans-to-cis isomerization or degradation. Here, we combined zebrafish CreERT2 recombination experiments and cell culture assays to document the gradual activity loss of trans-4-OHT and describe the alternative Tamoxifen metabolite Endoxifen as more stable alternative compound. Endoxifen retains potent activation upon prolonged storage (3 months), yet consistently induces half the ERT2 domain fusion activity compared to fresh trans-4-OHT. Using 1H-NMR analysis, we reveal that trans-4-OHT isomerization is undetectable upon prolonged storage in either DMSO or Ethanol, ruling out isomer transformation as cause for the gradual loss of trans-4-OHT activity. We further establish that both trans-4-OHT and Endoxifen are insensitive to light exposure under regular laboratory handling conditions. We attribute the gradual loss of trans-4-OHT potency to precipitation over time, and show that heating of aged trans-4-OHT aliquots reinstates their CreERT2 induction potential. Our data establish Endoxifen as potent and reproducible complementary compound to 4-OHT to control ERT2 domain fusion proteins in vivo, and provide a framework for efficient chemically controlled recombination experiments.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc16027545
003      
CZ-PrNML
005      
20161005132136.0
007      
ta
008      
161005s2016 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1371/journal.pone.0152989 $2 doi
024    7_
$a 10.1371/journal.pone.0152989 $2 doi
035    __
$a (PubMed)27077909
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Felker, Anastasia $u Institute of Molecular Life Sciences, University of Zürich, Zürich, Switzerland.
245    10
$a In Vivo Performance and Properties of Tamoxifen Metabolites for CreERT2 Control / $c A. Felker, S. Nieuwenhuize, A. Dolbois, K. Blazkova, C. Hess, LW. Low, S. Burger, N. Samson, TJ. Carney, P. Bartunek, C. Nevado, C. Mosimann,
520    9_
$a Mutant Estrogen Receptor (ERT2) ligand-binding domain fusions with Cre recombinase are a key tool for spatio-temporally controlled genetic recombination with the Cre/lox system. CreERT2 is efficiently activated in a concentration-dependent manner by the Tamoxifen metabolite trans-4-OH-Tamoxifen (trans-4-OHT). Reproducible and efficient Cre/lox experimentation is hindered by the gradual loss of CreERT2 induction potency upon prolonged storage of dissolved trans-4-OHT, which potentially results from gradual trans-to-cis isomerization or degradation. Here, we combined zebrafish CreERT2 recombination experiments and cell culture assays to document the gradual activity loss of trans-4-OHT and describe the alternative Tamoxifen metabolite Endoxifen as more stable alternative compound. Endoxifen retains potent activation upon prolonged storage (3 months), yet consistently induces half the ERT2 domain fusion activity compared to fresh trans-4-OHT. Using 1H-NMR analysis, we reveal that trans-4-OHT isomerization is undetectable upon prolonged storage in either DMSO or Ethanol, ruling out isomer transformation as cause for the gradual loss of trans-4-OHT activity. We further establish that both trans-4-OHT and Endoxifen are insensitive to light exposure under regular laboratory handling conditions. We attribute the gradual loss of trans-4-OHT potency to precipitation over time, and show that heating of aged trans-4-OHT aliquots reinstates their CreERT2 induction potential. Our data establish Endoxifen as potent and reproducible complementary compound to 4-OHT to control ERT2 domain fusion proteins in vivo, and provide a framework for efficient chemically controlled recombination experiments.
650    _2
$a zvířata $7 D000818
650    _2
$a buněčné linie $7 D002460
650    _2
$a stabilita léku $7 D004355
650    _2
$a vysoká teplota $7 D006358
650    _2
$a lidé $7 D006801
650    _2
$a integrasy $x genetika $7 D019426
650    _2
$a terciární struktura proteinů $7 D017434
650    _2
$a receptory pro estrogeny $x chemie $x genetika $7 D011960
650    _2
$a rekombinantní fúzní proteiny $x chemie $x genetika $7 D011993
650    _2
$a rekombinace genetická $x účinky léků $7 D011995
650    _2
$a stereoizomerie $7 D013237
650    _2
$a tamoxifen $x analogy a deriváty $x chemie $x metabolismus $x farmakologie $7 D013629
650    _2
$a časové faktory $7 D013997
650    _2
$a dánio pruhované $7 D015027
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Nieuwenhuize, Susan $u Institute of Molecular Life Sciences, University of Zürich, Zürich, Switzerland.
700    1_
$a Dolbois, Aymeric $u Department of Chemistry, University of Zürich, Zürich, Switzerland.
700    1_
$a Blazkova, Kristyna $u CZ-OPENSCREEN, Institute of Molecular Genetics of the ASCR, v.v.i., Prague, Czech Republic.
700    1_
$a Hess, Christopher $u Institute of Molecular Life Sciences, University of Zürich, Zürich, Switzerland.
700    1_
$a Low, Larry W L $u Institute of Molecular and Cell Biology (IMCB), A*STAR, Biopolis Drive, Singapore, Singapore.
700    1_
$a Burger, Sibylle $u Institute of Molecular Life Sciences, University of Zürich, Zürich, Switzerland.
700    1_
$a Samson, Natasha $u Institute of Molecular Life Sciences, University of Zürich, Zürich, Switzerland.
700    1_
$a Carney, Tom J $u Institute of Molecular and Cell Biology (IMCB), A*STAR, Biopolis Drive, Singapore, Singapore. Lee Kong Chian School of Medicine, Nanyang Technological University, 50 Nanyang Avenue, Singapore, Singapore.
700    1_
$a Bartunek, Petr $u CZ-OPENSCREEN, Institute of Molecular Genetics of the ASCR, v.v.i., Prague, Czech Republic.
700    1_
$a Nevado, Cristina $u Department of Chemistry, University of Zürich, Zürich, Switzerland.
700    1_
$a Mosimann, Christian $u Institute of Molecular Life Sciences, University of Zürich, Zürich, Switzerland.
773    0_
$w MED00180950 $t PloS one $x 1932-6203 $g Roč. 11, č. 4 (2016), s. e0152989
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27077909 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20161005 $b ABA008
991    __
$a 20161005132523 $b ABA008
999    __
$a ok $b bmc $g 1165859 $s 952175
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 11 $c 4 $d e0152989 $e 20160414 $i 1932-6203 $m PLoS One $n PLoS One $x MED00180950
LZP    __
$a Pubmed-20161005

Find record

Citation metrics

Archiving options